Takeda and Frazier Healthcare Partners are together launching HilleVax, a biopharmaceutical company to develop and commercialise the former’s norovirus vaccine candidate.
Takeda has granted a license to HilleVax for the exclusive development and commercialisation rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan.
Takeda will retain commercialisation rights in Japan and HilleVax will integrate certain Japan development activities into its global development.
Takeda remains committed to vaccines and this collaboration allows Takeda to focus primarily on dengue, COVID-19, pandemic influenza and Zika.
HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well-tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection.
To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects.
“The announcement of our partnership with Frazier Healthcare Partners will allow Takeda to focus efforts and resources on vaccines for diseases prevalent across Africa and provide support in alleviating the growing burden that infectious diseases have on public health systems,” said Ursula Belinda Myles, General Manager of Takeda’s Access Market Cluster.